QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.22 (+0.35%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.86 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.22 (+0.35%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.86 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.22 (+0.35%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.86 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.22 (+0.35%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.86 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Evotec Stock Price, News & Analysis (ETR:EVT)

€18.20
-0.61 (-3.24%)
(As of 11/27/2023 ET)
Compare
Today's Range
€18.11
▼
€18.97
50-Day Range
€15.74
▼
€21.58
52-Week Range
€14.80
▼
€24.44
Volume
247,921 shs
Average Volume
1.36 million shs
Market Capitalization
$3.22 billion
P/E Ratio
N/A
Dividend Yield
2.63%
Price Target
€28.00
Stock AnalysisAnalyst ForecastsChartHeadlines

EVT stock logo

About Evotec Stock (ETR:EVT)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVT Stock Price History

EVT Stock News Headlines

November 8, 2023 | markets.businessinsider.com
Evotec 9-month Adj. EBITDA, Revenues Rise; Confirms FY23, Mid-term Outlook
November 8, 2023 | finance.yahoo.com
Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update
November 28, 2023 | RYSE INC. (Ad)
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
November 7, 2023 | fxstreet.com
Flat start to Monday after global equities posted best week in a year
October 6, 2023 | finance.yahoo.com
Further weakness as Evotec (ETR:EVT) drops 6.5% this week, taking three-year losses to 23%
October 5, 2023 | markets.businessinsider.com
EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
September 27, 2023 | markets.businessinsider.com
EQS-News: Evotec SE: Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
September 26, 2023 | finance.yahoo.com
Evotec and Novo Nordisk Launch LAB eN(2) to Accelerate Translation in Cardiometabolic Diseases
November 28, 2023 | Autonomix (Ad)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
August 29, 2023 | markets.businessinsider.com
EQS-News: Evotec SE reports results for the first half-year 2023 and provides corporate updates
July 28, 2023 | markets.businessinsider.com
EQS-Adhoc: Evotec provides update on financial impact of cyber-attack
July 28, 2023 | markets.businessinsider.com
EQS-News: Evotec provides update on financial impact of cyber-attack
July 11, 2023 | markets.businessinsider.com
EQS-News: Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
June 29, 2023 | finanznachrichten.de
Evotec SE: Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
June 20, 2023 | markets.businessinsider.com
EQS-News: Evotec SE Annual General Meeting 2023 approves all proposed agenda items
June 20, 2023 | finance.yahoo.com
Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
June 8, 2023 | markets.businessinsider.com
Citi upgrades Evotec AG (EVO) to a Buy
June 8, 2023 | msn.com
WARBURG RESEARCH GMBH Maintains Evotec SE (FWB:EVT) Buy Recommendation
June 5, 2023 | finanznachrichten.de
Evotec SE: Evotec Presents Sustainability Strategy
June 5, 2023 | markets.businessinsider.com
EQS-News: Evotec presents sustainability strategy
June 2, 2023 | finanznachrichten.de
Evotec SE: Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
May 9, 2023 | markets.businessinsider.com
EQS-Adhoc: Just Evotec Biologics enters strategic biosimilars partnership with Sandoz
May 9, 2023 | markets.businessinsider.com
EQS-News: Just Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
May 9, 2023 | finance.yahoo.com
Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing
April 10, 2023 | markets.businessinsider.com
EQS-News: Evotec SE provides update on cyber attack
March 28, 2023 | uk.finance.yahoo.com
Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
March 28, 2023 | finanznachrichten.de
Evotec SE: Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership
See More Headlines
Receive EVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ETR
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
ETR:EVT
CUSIP
N/A
CIK
N/A
Web
www.evotec.com
Phone
+49-40-560810
Fax
N/A
Employees
5,067
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
€28.00
High Stock Price Target
€34.00
Low Stock Price Target
€21.00
Potential Upside/Downside
+53.8%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
(€0.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
29.81
P/E Growth
0.98
Net Income
$-94,980,000.00
Net Margins
-11.57%
Pretax Margin
N/A
Return on Equity
-8.02%
Return on Assets
0.17%

Debt

Debt-to-Equity Ratio
51.61
Current Ratio
2.16
Quick Ratio
2.97

Sales & Book Value

Annual Sales
$820.80 million
Price / Sales
3.93
Cash Flow
€5.27 per share
Price / Cash Flow
3.45
Book Value
€6.45 per share
Price / Book
2.82

Miscellaneous

Outstanding Shares
177,190,000
Free Float
N/A
Market Cap
$3.22 billion
Optionable
Not Optionable
Beta
1.11
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover
10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Werner Lanthaler M.B.A. (Age 55)
    MPA, Ph.D., Chairman of Management Board & CEO
    Comp: $1.32M
  • Dr. Cord Dohrmann Ph.D. (Age 59)
    Chief Scientific Officer & Member of Management Board
    Comp: $804k
  • Dr. Craig Johnstone Ph.D. (Age 53)
    COO & Member of Management Board
    Comp: $712k
  • Dr. Matthias Evers Ph.D. (Age 50)
    Chief Business Officer & Member of Management Board
    Comp: $636k
  • Ms. Laetitia Rouxel (Age 49)
    CFO & Member of Management Board
  • Ms. Anja Bosler
    Principal Accounting Officer and Senior Vice President of Group Accounting
  • Mr. Volker Braun
    Senior VP and Global Head of Investor Relations & ESG
  • Dr. Christian Dargel
    EVP Global Head of Legal & Compliance
  • Gabriele Hansen
    Senior VP & Head of Global Corporate Communications & Marketing
  • Ms. Monika Conradt
    Global Head of Human Resources

Key Competitors

View All Competitors














EVT Stock Analysis - Frequently Asked Questions

What is Evotec's stock price target for 2024?

0 brokerages have issued 1-year price objectives for Evotec's shares. Their EVT share price targets range from €21.00 to €34.00. On average, they predict the company's share price to reach €28.00 in the next year. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for EVT or view top-rated stocks among Wall Street analysts.

How have EVT shares performed in 2023?

Evotec's stock was trading at €15.26 at the beginning of 2023. Since then, EVT shares have increased by 19.3% and is now trading at €18.20.
View the best growth stocks for 2023 here.

What other stocks do shareholders of Evotec own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evotec investors own include Agilent Technologies (A), AbbVie (ABBV), ACADIA Pharmaceuticals (ACAD), Anthem (ANTM), AxoGen (AXGN), Bank of America (BAC), Booz Allen Hamilton (BAH), Biohaven (BHVN), Biogen (BIIB) and Blueprint Medicines (BPMC).

This page (ETR:EVT) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -